Efficacy of Unani drugs on Melasma
Phase 2
- Conditions
- Health Condition 1: L814- Other melanin hyperpigmentation
- Registration Number
- CTRI/2022/04/041617
- Lead Sponsor
- ational Institute of Unani Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients with Fitzpatrick Skin phototype 3rd to 6th
Patients m MASI Score up to Marked in Darkness (0-3) and <= 49 % in Area
Duration of Melasma <= 3 Yrs.
Patient willing for study
Exclusion Criteria
Pregnant and Lactating women
Patients with systemic disease e.g. Malignancy, Thyroid Dysfunction, CKD, Tuberculosis.
History of any Skin therapies related to Hyperpigmentation
History of Hypersensitivity Reaction with Drugs.
Severe Cases of Melasma
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reversal of mMASI, PGA, PtGA, scores <br/ ><br>Change in photographic lesionTimepoint: 28 days
- Secondary Outcome Measures
Name Time Method ATimepoint: NA